{{Drugbox
| Verifiedfields = changed
| Watchedfields = changed
| verifiedrevid = 444488130
| IUPAC_name = (2-Methyl-1-propyl-1H-indol-3-yl)-1-naphthalenylmethanone
| image = JWH-015.svg

<!--Clinical data-->
| tradename =  
| pregnancy_AU = <!-- A / B1 / B2 / B3 / C / D / X -->
| pregnancy_US = <!-- A / B            / C / D / X -->
| pregnancy_category =  
| legal_AU = <!-- Unscheduled / S2 / S3 / S4 / S5 / S6 / S7 / S8 / S9 -->
| legal_CA = Schedule II
| legal_UK = <!-- GSL         / P       / POM / CD / Class A, B, C -->
| legal_US = <!-- OTC                   / Rx-only  / Schedule I, II, III, IV, V -->
| legal_DE = Anlage II
| routes_of_administration =

<!--Pharmacokinetic data-->
| bioavailability =  
| protein_bound =  
| metabolism =  
| elimination_half-life =  
| excretion =

<!--Identifiers-->
| IUPHAR_ligand = 5558
| CAS_number_Ref = {{cascite|correct|??}}
| CAS_number = 155471-08-2
| ATC_prefix =  
| ATC_suffix =  
| PubChem = 4273754
| DrugBank_Ref = {{drugbankcite|correct|drugbank}}
| DrugBank =  
| ChemSpiderID_Ref = {{chemspidercite|changed|chemspider}}
| ChemSpiderID      = 3480676

<!--Chemical data-->
| C=23 | H=21 | N=1 | O=1 
| molecular_weight = 327.43 g/mol
| smiles            = CCCN1C(=C(C2=CC=CC=C21)C(=O)C3=CC=CC4=CC=CC=C43)C
| StdInChI_Ref = {{stdinchicite|changed|chemspider}}
| StdInChI          = 1S/C23H21NO/c1-3-15-24-16(2)22(20-12-6-7-14-21(20)24)23(25)19-13-8-10-17-9-4-5-11-18(17)19/h4-14H,3,15H2,1-2H3
| StdInChIKey_Ref = {{stdinchicite|changed|chemspider}}
| StdInChIKey       = LJSBBBWQTLXQEN-UHFFFAOYSA-N
}}

'''JWH-015''' is a chemical from the [[naphthoylindole]] family that acts as a subtype-selective [[cannabinoid]] agonist. Its affinity for [[Cannabinoid receptor 2 (macrophage)|CB<sub>2</sub> receptors]] is 13.8 nM, while its affinity for [[Cannabinoid receptor 1|CB<sub>1</sub>]] is 383 nM, meaning that it binds almost 28x more strongly to CB<sub>2</sub> than CB<sub>1</sub><ref name="pmid10940540">{{cite journal |vauthors=Aung MM, Griffin G, Huffman JW, Wu M, Keel C, Yang B, Showalter VM, Abood ME, Martin BR | title = Influence of the N-1 alkyl chain length of cannabimimetic indoles upon CB<sub>1</sub> and CB<sub>2</sub>)receptor binding | journal = Drug Alcohol Depend | volume = 60 | issue = 2 | pages = 133–40 |date=August 2000 | pmid = 10940540 | doi =10.1016/S0376-8716(99)00152-0 }}</ref> However it still displays some CB<sub>1</sub> activity, and in some model systems can be very potent and efficacious at activating CB<sub>1</sub> receptors,<ref name="pmid22921769">{{cite journal |vauthors=Murataeva N, Mackie K, Straiker A | title = The CB2-preferring agonist JWH015 also potently and efficaciously activates CB1 in autaptic hippocampal neurons | journal = Pharmacol. Res. | volume = 66 | issue = 5 | pages = 437–42 |date=November 2012 | pmid = 22921769 | doi = 10.1016/j.phrs.2012.08.002 | pmc = 3601544 }}</ref> and therefore it is not as selective as newer drugs such as [[JWH-133]].<ref name="pmid18289088">{{cite journal |vauthors=Marriott KS, Huffman JW | title = Recent advances in the development of selective ligands for the cannabinoid CB(2) receptor | journal = Curr Top Med Chem | volume = 8 | issue = 3 | pages = 187–204 | year = 2008 | pmid = 18289088 | doi = 10.2174/156802608783498014 }}</ref> It has been shown to possess [[immunomodulatory]] effects,<ref name="pmid16503355">{{cite journal |vauthors=Ghosh S, Preet A, Groopman JE, Ganju RK | title = Cannabinoid receptor CB2 modulates the CXCL12/CXCR4-mediated chemotaxis of T lymphocytes | journal = Mol. Immunol. | volume = 43 | issue = 14 | pages = 2169–79 |date=July 2006 | pmid = 16503355 | doi = 10.1016/j.molimm.2006.01.005 }}</ref><ref name="pmid18178718">{{cite journal |vauthors=Montecucco F, Burger F, Mach F, Steffens S | title = CB2 cannabinoid receptor agonist JWH-015 modulates human monocyte migration through defined intracellular signaling pathways | journal = Am. J. Physiol. Heart Circ. Physiol. | volume = 294 | issue = 3 | pages = H1145–55 |date=March 2008 | pmid = 18178718 | doi = 10.1152/ajpheart.01328.2007 }}</ref> and CB<sub>2</sub> agonists may be useful in the treatment of pain and inflammation.<ref name="pmid1352348">{{cite journal |vauthors=Balter MB, Uhlenhuth EH | title = Prescribing and use of benzodiazepines: an epidemiologic perspective | journal = J Psychoactive Drugs | volume = 24 | issue = 1 | pages = 63–4 | year = 1992 | pmid = 1352348 | doi = 10.1080/02791072.1992.10471620 }}</ref><ref name="pmid17413917">{{cite journal |vauthors=Romero-Sandoval A, Eisenach JC | title = Spinal cannabinoid receptor type 2 activation reduces hypersensitivity and spinal cord glial activation after paw incision | journal = Anesthesiology | volume = 106 | issue = 4 | pages = 787–94 |date=April 2007 | pmid = 17413917 | doi = 10.1097/01.anes.0000264765.33673.6c }}</ref> It was discovered and named after Dr. [[John W. Huffman]].

==Metabolism==
JWH-015 has been shown ''in vitro'' to be metabolised primarily by [[hydroxylation]] and N-[[dealkylation]], and also by [[epoxidation]] of the [[naphthalene]] ring,<ref>{{cite journal | vauthors = Zhang Q, Ma P, Cole RB, Wang G | date = Nov 2006 | title = Identification of in vitro metabolites of JWH-015, an aminoalkylindole agonist for the peripheral cannabinoid receptor (CB2) by HPLC-MS/MS. | url = | journal = Analytical and Bioanalytical Chemistry | volume = 386 | issue = 5| pages = 1345–55 | doi = 10.1007/s00216-006-0717-6 | pmid = 16955257 }}</ref> similar to the metabolic pathways seen for other [[aminoalkylindole]] [[cannabinoids]] such as [[WIN 55,212-2]].<ref name="pmid12228183">{{cite journal |vauthors=Zhang Q, Ma P, Iszard M, Cole RB, Wang W, Wang G | title = In vitro metabolism of R(+)-[2,3-dihydro-5-methyl-3-[(morpholinyl)methyl]pyrrolo [1,2,3-de]1,4-benzoxazinyl]-(1-naphthalenyl) methanone mesylate, a cannabinoid receptor agonist | journal = Drug Metab. Dispos. | volume = 30 | issue = 10 | pages = 1077–86 |date=October 2002 | pmid = 12228183 | doi = 10.1124/dmd.30.10.1077 }}</ref> [[Epoxidation]] of [[polycyclic aromatic hydrocarbon]]s (see for example  [[Benzo(a)pyrene#Toxicity|benzo(a)pyrene toxicity]]) can produce [[carcinogenic]] metabolites, although there is no evidence to show that JWH-015 or other aminoalkylindole cannabinoids are actually carcinogenic ''in vivo''.  A study published in the British Journal of Cancer shows that JWH-015 may signal certain cancers to shrink through a process called apoptosis.<ref>{{cite journal|author=N Olea-Herrero|author2=D Vara|author3=S Malagarie-Cazenave|author4=I Díaz-Laviada|title=Inhibition of human tumour prostate PC-3 cell growth by cannabinoids R(+)-Methanandamide and JWH-015: Involvement of CB2|journal=British Journal of Cancer|date=18 August 2009|pages=101, 940–950|doi=10.1038/sj.bjc.6605248|url=http://www.nature.com/bjc/journal/v101/n6/abs/6605248a.html|accessdate=10 July 2014|volume=101|pmid=19690545|pmc=2743360}}</ref>

==Legal Status==

As of October 2015 JWH-015 is a controlled substance in China.<ref>{{cite web | url=http://www.sfda.gov.cn/WS01/CL0056/130753.html | title=关于印发《非药用类麻醉药品和精神药品列管办法》的通知 | publisher=China Food and Drug Administration | date=27 September 2015 | language=Chinese | accessdate=1 October 2015}}</ref>

==References==
{{reflist|35em}}

{{Cannabinoids}}

[[Category:Cannabinoids]]
[[Category:Naphthoylindoles]]
[[Category:JWH cannabinoids]]
[[Category:Designer drugs]]
[[Category:CB1 receptor agonists]]
[[Category:CB2 receptor agonists]]


{{cannabinoid-stub}}